|UNAIDS-Sponsored Regional Workshops to Discuss Ethical Issues in Preventive HIV Vaccine Trials (UNAIDS, 2000, 52 p.)|
|OURO PRETO, BRAZIL, 1-3 APRIL, 1998|
A discussion about intellectual property needs to take place early in the process of proposal development. It may be reasonable for the host country to claim a right to intellectual property if its participation in the trial is deemed essential for the development of the particular candidate vaccine.
Intellectual property may become an important commodity in the negotiation of vaccine availability to the host country following the trial. However, access to a successful vaccine following the trial should be dealt with separately from the question of who has the right to intellectual property.
It is not clear who in the host country (investigators, government, and population) should have a claim to the intellectual property rights, though a majority was of the opinion that this should not be the exclusive property of the investigators.